A5048053941- Thyroid Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- Crystallography and molecular interactions
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
- Layered Double Hydroxides Synthesis and Applications
- Bladder and Urothelial Cancer Treatments
- Hormonal Regulation and Hypertension
- Advanced Proteomics Techniques and Applications
- Polyoxometalates: Synthesis and Applications
- Proteoglycans and glycosaminoglycans research
- Virus-based gene therapy research
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Ubiquitin and proteasome pathways
- Mitochondrial Function and Pathology
- Sarcoma Diagnosis and Treatment
Shihezi University
2025
University of South China
2025
Hunan Cancer Hospital
2020-2023
Zhongda Hospital Southeast University
2023
First Affiliated Hospital of Xi'an Jiaotong University
2023
Xi'an Jiaotong University
2023
Central South University
2022
Jilin University
2017
Massachusetts General Hospital
2016
Alhough antiangiogenic agents are the bedrock of treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), novel with optimized features like greater target-binding affinities and more favorable pharmacokinetics profile needed. This phase II randomized, double-blind, placebo-controlled trial investigated efficacy safety anlotinib, a multikinase inhibitor, RAIR-DTC.Patients (ages between 18 70 years) pathologically confirmed locally advanced or metastatic RAIR-DTC were...
The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.This multicenter, double-blind, placebo-controlled, III enrolled 191 RAIR-DTC randomized a ratio 2:1 (300 mg twice daily,...
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>